Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 208

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 16F
Chunk 208
---
 accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on Ceapro’s consolidated financial statements, and neither a written report nor oral advice was provided to Ceapro that Deloitte LLP concluded was an important factor considered by Ceapro in reaching a decision as to any accounting, auditing, or financial reporting issue, or (b) any matter that was the subject of a disagreement (as defined in Item 16F(a)(1)(iv) of the instructions to Form 20-F and the related instructions therein) or a reportable event (as defined in Item 16F(a)(1)(v) of the instructions to Form 20-F).